26 Sep CREATE Medicines
Posted at 15:30h
in
Daniel Getts, Ph.D., CEO
Oct. 6 | 3:00pm | FLW Ballroom G
Cambridge, MA
(Private)
CREATE Medicines is pioneering multi-immune programming with its versatile in vivo CAR platform. Our proprietary mRNA-LNP CARs and targeted receptor/LNP technologies enable direct programming of T cells, NK cells, and myeloid cells within the body—demonstrating first-in-human evidence of uptake, expression, and tolerable repeat dosing.
What sets CREATE apart:
• Proprietary receptor and RNA engineering, including retrotransposon-mediated stability options
• Multi-lineage programming across immune cell types (T, NK, myeloid)
• First-in-human clinical data confirming mechanism of action
• Demonstrated tolerability with repeat dosing
